Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism

被引:170
作者
Hundemer, Gregory L. [1 ,2 ,3 ]
Curhan, Gary C. [1 ,2 ,3 ,4 ]
Yozamp, Nicholas [2 ,3 ]
Wang, Molin [2 ,3 ,4 ]
Vaidya, Anand [2 ,3 ,5 ]
机构
[1] Brigham & Womens Hosp, Dept Med, Div Renal Med, 75 Francis St, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA USA
[3] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA
[4] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Dept Biostat, Boston, MA USA
[5] Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, Ctr Adrenal Disorders, 75 Francis St, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
ARTERIAL-HYPERTENSION; HYPERALDOSTERONISM; EPLERENONE;
D O I
10.1001/jamacardio.2018.2003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Primary aldosteronism (PA) is an ideal condition to evaluate the role of the mineralocorticoid receptor (MR) in the pathogenesis of atrial fibrillation (AF). OBJECTIVE To investigate whether MR antagonist therapy or surgical adrenalectomy in PA influence the risk for incident AF. DESIGN This cohort study included patients aged 18 years and older. Patients with PA and age-matched patients with essential hypertension were identified via electronic health records. Patients with a history of AF, myocardial infarction, congestive heart failure, or stroke were excluded. Data were collected between 1991 and the end of 2016 in an academic medical center, with a mean follow-up duration of approximately 8 years. EXPOSURES Patients with PA treated with MR antagonists or surgical adrenalectomy were compared with patients with essential hypertension. Patients with PA who were treated with MR antagonists were categorized by whether their plasma renin activity remained suppressed (< 1 ng/mL/h) or substantially increased (>= 1 ng/mL/h), as proxies for insufficient or sufficient MR blockade. MAIN OUTCOMES AND MEASURE Incident AF. RESULTS A total of 195 patients with PA who were treated with MR antagonists and 201 patients with PA treated with surgical adrenalectomy were included, as well as 40 092 age-matched patients with essential hypertension. Despite similar blood pressure at study entry and throughout follow-up, patients with PA who were treated with MR antagonists whose renin remained suppressed had a higher risk for incident AF than patients with essential hypertension (adjusted HR, 2.55 [95% CI, 1.75-3.71]). They also had an adjusted 10-year cumulative AF incidence difference of 14.1(95% CI, 6.7-21.5) excess cases per 100 persons compared with patients with essential hypertension. In contrast, patients with PA who were treated with MR antagonists and whose renin increased and patients with PA who were treated with surgical adrenalectomy had no statistically significant difference in risk for incident AF compared with patients with essential hypertension. CONCLUSIONS AND RELEVANCE When compared with patients with essential hypertension, patients with PA treated with MR antagonists such that renin remained suppressed (as a proxy for insufficient MR blockade) had a significantly higher risk for incident AF; however, treatment of PA with MR antagonists to substantially increase renin (suggesting sufficient MR blockade), or with surgical adrenalectomy (to remove the source of aldosteronism), was associated with no significant difference in risk for developing AF. These findings add to the growing body of evidence suggesting that MR blockade may be a potential therapy to decrease the incidence of AF.
引用
收藏
页码:768 / 774
页数:7
相关论文
共 15 条
  • [1] The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension A Cohort Study
    Brown, Jenifer M.
    Robinson-Cohen, Cassianne
    Luque-Fernandez, Miguel Angel
    Allison, Matthew A.
    Baudrand, Rene
    Ix, Joachim H.
    Kestenbaum, Bryan
    de Boer, Ian H.
    Vaidya, Anand
    [J]. ANNALS OF INTERNAL MEDICINE, 2017, 167 (09) : 630 - +
  • [2] Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry
    Fudim, Marat
    Liu, Peter R.
    Shrader, Peter
    Blanco, Rosalia G.
    Allen, Larry A.
    Fonarow, Gregg C.
    Gersh, Bernard J.
    Kowey, Peter R.
    Mahaffey, Kenneth W.
    Hylek, Elaine
    Go, Alan S.
    Thomas, Laine
    Peterson, Eric D.
    Piccini, Jonathan P.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (08):
  • [3] The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline
    Funder, John W.
    Carey, Robert M.
    Mantero, Franco
    Murad, M. Hassan
    Reincke, Martin
    Shibata, Hirotaka
    Stowasser, Michael
    Young, William F., Jr.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (05) : 1889 - 1916
  • [4] Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study
    Hundemer, Gregory L.
    Curhan, Gary C.
    Yozamp, Nicholas
    Wang, Molin
    Vaidya, Anand
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (01) : 51 - 59
  • [5] The Mineralocorticoid Receptor Promotes Fibrotic Remodeling in Atrial Fibrillation
    Lavall, Daniel
    Selzer, Christian
    Schuster, Pia
    Lenski, Matthias
    Adam, Oliver
    Schaefers, Hans-Joachim
    Boehm, Michael
    Laufs, Ulrich
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (10) : 6656 - 6668
  • [6] Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis
    Monticone, Silvia
    D'Ascenzo, Fabrizio
    Moretti, Claudio
    Williams, Tracy Ann
    Veglio, Franco
    Gaita, Fiorenzo
    Mulatero, Paolo
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (01) : 41 - 50
  • [7] Aldosterone Pathway Blockade to Prevent Atrial Fibrillation: A Systematic Review and Meta-Analysis
    Neefs, J.
    van den Berg, N. W. E.
    Limpens, J.
    Berger, W. R.
    Boekholdt, S. M.
    Sanders, P.
    de Groot, J. R.
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 231 : 155 - 161
  • [8] Hyperaldosteronism induces left atrial systolic and diastolic dysfunction
    Reil, Jan-Christian
    Tauchnitz, Marcus
    Tian, Qinghai
    Hohl, Mathias
    Linz, Dominik
    Oberhofer, Martin
    Kaestner, Lars
    Reil, Gert-Hinrich
    Thiele, Holger
    Steendijk, Paul
    Boehm, Michael
    Neuberger, Hans-Ruprecht
    Lipp, Peter
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2016, 311 (04): : H1014 - H1023
  • [9] Aldosterone promotes atrial fibrillation
    Reil, Jan-Christian
    Hohl, Mathias
    Selejan, Simina
    Lipp, Peter
    Drautz, Fabian
    Kazakow, Andrey
    Muenz, Benedikt M.
    Mueller, Patrick
    Steendijk, Paul
    Reil, Gert-Hinrich
    Allessie, Maurits A.
    Boehm, Michael
    Neuberger, Hans-Ruprecht
    [J]. EUROPEAN HEART JOURNAL, 2012, 33 (16) : 2098 - 2108
  • [10] Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term
    Rossi, Gian Paolo
    Maiolino, Giuseppe
    Flego, Alberto
    Belfiore, Anna
    Bernini, Giampaolo
    Fabris, Bruno
    Ferri, Claudio
    Giacchetti, Gilberta
    Letizia, Claudio
    Maccario, Mauro
    Mallamaci, Francesca
    Muiesan, Maria Lorenza
    Mannelli, Massimo
    Negro, Aurelio
    Palumbo, Gaetana
    Parenti, Gabriele
    Rossi, Ermanno
    Mantero, Franco
    [J]. HYPERTENSION, 2018, 71 (04) : 585 - 591